Kyrgyzstan suspends sale of Dok-1 Max
Kyrgyzstan has suspended the sale of Dok-1 Max drug. Press center of the Ministry of Health reported, citing the Department of Medicines and Medical Products.
According to the department, mass mortality among children has been registered in Uzbekistan, presumably associated with the use of Dok-1 Max drug, produced by the Indian company Marion Biotech Pvt.
This is a combined preparation containing the following active substances: paracetamol, guaifenesin, phenylephrine; it is recommended for symptomatic treatment of acute respiratory viral infections and influenza, accompanied by fever, headache, sore throat, productive cough. Dok-1 Max is produced in the form of pills and syrup; it was registered in Kyrgyzstan in 2018, the last import was in 2021, there was no import into the country in 2022.
Given the current situation, it was decided to temporarily suspend its sale from December 23, 2022 in the territory of the Kyrgyz Republic. The samples were sent to the Central Control and Analytical Laboratory for tests.
Physicians remind that anyone can report suspected side effects to the Department of Medicines and Medical Products.
There have been no reports of adverse reactions to the Dok-1 Max to the department.
According to the Uzbek media, a message appeared on social media that 21 children, who took pills and syrup Dok-1 Max (India) had complications, 15 children died for two months in Samarkand region. An investigation has been launched. Its sale has been suspended.
